They discovered that gain-of-function mutations in the KIT proto-oncogene are consistently associated with elevated serum levels of galectins -1, -3, -8, and -9 in breast cancer and galectin-1 in non-small cell lung cancer patients. This evidence concerns the gene LGALS1 and non-small cell lung carcinoma.